Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT06623318 · ClinicalTrials.gov registry record · NA
IV Ensure in Patients Receiving OPAT
A NA study of Determine If Adherence Rates with IV Antibiotics in OPAT Have a Correlation to Hospital Readmission Rates, sponsored by IV Ensure.
- Recruiting
- Registry status
- NA
- Development phase
- 90
- Enrollment target
- 1
- Study location
NCT06623318: Recruiting NA study of Determine If Adherence Rates with IV Antibiotics in OPAT Have a Correlation to Hospital Readmission Rates, sponsored by IV Ensure.
NCT06623318 is a NA study of Determine If Adherence Rates with IV Antibiotics in OPAT Have a Correlation to Hospital Readmission Rates that is actively recruiting participants, run by IV Ensure. The registered enrollment target is 90 participants, below the 1,404-participant average among 58,714 other NA trials with a reported enrollment target (94% lower). The trial reports 1 study location across 1 state. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT06623318, a NA study of Determine If Adherence Rates with IV Antibiotics in OPAT Have a Correlation to Hospital Readmission Rates, is actively recruiting participants, sponsored by IV Ensure.
- RECRUITING
- Registry status
- NA
- Development phase
- 90 participants
- Enrollment target
- 1
- Study location
Study Summary
The purpose of remote therapeutic monitoring is to provide oversight and evaluation of patients receiving IV medications in the home setting post-acute. The goal is to improve patient outcomes and decrease re-admission rates for related diagnoses due to poor adherence. Remote therapeutic monitoring provides data used in the determination of dates, times, and duration of doses administered in the home setting to support real-time intervention by dedicated care managers to support improved adherence with prescribed dosing regiments. The objectives of the study are to: 1. Determine adherence rates for IV medications administered in the home. 2. Assess re-admission against adherence rates.
Primary Outcome
This will be defined as a dichotomous outcome variable with Yes occurring when (a) a patients ID reoccurs in the OU Medicine EMR/EHR data pull within 30 days of their discharge with IV Ensure remote therapeutic monitoring device and (b) the patients readmissions reason matched the pre-specified list of ICD codes corresponding to secondary or downstream infections. If both of the above do not occur, the readmission variable will be set to No.
Conditions Studied
Interventions
- DEVICE Remote therapeutic monitoring device
Study Locations (1)
Oklahoma
- The University of Oklahoma Health Sciences Center - Oklahoma City
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 90 participants |
| Start Date | 2023-08-23 |
| Est. Completion | 2024-11 |
| Phase | NA |
What NCT06623318 shows while recruiting
NCT06623318 is an interventional study that assigns participants to a tested intervention. The registry caps enrollment at 90 participants, a relatively small participant target, below the 1,404-participant average among 58,714 other NA trials with a reported enrollment target (94% lower).
The record links to 1 condition, with Determine If Adherence Rates with IV Antibiotics in OPAT Have a Correlation to Hospital Readmission Rates appearing as the primary indexed condition, and to 1 intervention - of which Remote therapeutic monitoring device is the first listed.
NCT06623318 reports a single indexed study location in Oklahoma.
Frequently Asked Questions
What is clinical trial NCT06623318 about?
NCT06623318 is a clinical study titled "IV Ensure in Patients Receiving OPAT". The purpose of remote therapeutic monitoring is to provide oversight and evaluation of patients receiving IV medications in the home setting post-acute. The goal is to improve patient outcomes and decrease re-admission rates for related diagnoses due to poor adherence. Remote therapeutic monitoring ...
What is the current status of trial NCT06623318?
This trial is currently recruiting. It is a NA study. The enrollment target is 90 participants. The study started on 2023-08-23. Estimated completion is 2024-11.
What conditions does trial NCT06623318 study?
This clinical trial studies the following conditions: Determine If Adherence Rates with IV Antibiotics in OPAT Have a Correlation to Hospital Readmission Rates.
What interventions are being tested in trial NCT06623318?
The interventions under investigation include: Remote therapeutic monitoring device (DEVICE).
Who is sponsoring clinical trial NCT06623318?
This trial is sponsored by IV Ensure, which has 1 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT06623318 being conducted?
This trial has 1 study location across Oklahoma. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
How this trial's enrollment target compares
Where NCT06623318's enrollment target sits among peer trials
90 942nd of 2000 higher than 1,029 of 2,000 other NA trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other NA trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT02521311 · 90 participants · Phase 2
Assessment of Clemastine Fumarate as a Remyelinating Agent in Acute Optic Neuritis (ReCOVER)
- NCT02939573 · 90 participants · Phase 2
A Randomized Multicenter Study for Isolated Skin Vasculitis
- NCT03128879 · 90 participants · Phase 2
Venetoclax With Ibrutinib or Acalabrutinib in Pts. With High-risk CLL
- NCT03184038 · 90 participants · NA
Neurocognition in Patients With Multiple Brain Metastases Treated With Radiosurgery
Similar registry start date
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia
- NCT07125183 · started 2026-12 · Phase 2
Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma
- NCT07292298 · started 2026-11 · Phase 2
Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates
- NCT04263285 · started 2026-10 · NA
Treatment of Depression Post-SCI